NCT03455777View on ClinicalTrials.gov

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 12, 2018

Primary Completion Date

September 30, 2018

Study Completion Date

December 31, 2018

Conditions
Homozygous Familial Hypercholesterolemia
Interventions
DRUG

AKCEA-ANGPTL3-LRX

Single open-label cohort

Trial Locations (1)

G1V4W2

Clinical Site, Québec

Sponsors

Lead Sponsor

Akcea Therapeutics
All Listed Sponsors
collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Akcea Therapeutics

INDUSTRY

NCT03455777 - Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) | Biotech Hunter | Biotech Hunter